Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 772

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 772
---
, without the need for any further approval of the Company’s shareholders, provided that the Sponsor (or its affiliates or permitted designees or a third party) will deposit into the Trust Account for each such one-monthextension an extension fee, unless the closing of the Company’s initial business combination has occurred, in exchange for a non-interestbearing promissory note payable upon consummation of an initial business combination. NOTE 11 – EVENTS (UNAUDITED) SUBSEQUENT TO THE DATE OF THE INDEPENDENT AUDITOR’S REPORT On April 2, 2025, the Company received a written letter from the Staff (the “Staff’s Determination”) stating that the Company has not regained compliance with the Listing Rules, and also that the Company is not in compliance with Nasdaq Listing Rule 5450(b)(2)(B) (the “Public Float Rule”), which requires the Company to maintain a minimum of 1,100,000publicly held shares for continued listing, and the Company’s securities will be delisted from The Nasdaq Global Markets unless the Company requests an appeal of this determination by April 9, 2025. If the Company does not appeal the Staff’s delisting determination by April 9, 2025, trading of the Company’s Class A ordinary shares, warrants and units will be suspended at the opening of business on April 11, 2025, and a Form 25-NSEwould be filed with the SEC, which would remove Denali’s securities from listing and registration on Nasdaq. Denali did not appeal the Staff’s delisting determination by April 9, 2025, and the Denali Class A ordinary shares, Public Warrants and Public Units were delisted at the opening of business on April 16, 2025. Trading of the Company’s securities on the OTC Markets commenced shortly after the delisting. On April 11, 2025, the shareholders of the Company held an extraordinary general meeting of shareholders to consider and vote upon a proposal to amend, by way of special resolution, the amended and restated memorandum and articles of association of the Company to extend the date by which the Company must either (i) consummate a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving the Company and one or more businesses or entities or (ii) cease its operations, except for the purpose of winding up, if it fails to complete such initial business combination and redeem 100% of the Company’s Class A ordinary